FDA Import Alert 66-41 Refreshed: DWPE and Peptide Imports in 2026

Import Alert 66-41, titled 'Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.,' is a standing enforcement instruction that FDA field divisions apply at ports of entry. According to FDA, it directs those divisions to detain, without physically examining each shipment, products that FDA has identified as unapproved new drugs being promoted in the United States. The alert is published on FDA's import-alert system and is one of several '66-series' alerts that address the drug-import space.

Per FDA's published change note on the alert, the revision dated 19 May 2026 updated the alert's guidance section, including agency contacts, rather than overhauling the legal mechanism itself. On that basis, the underlying DWPE authority and the structure of how products are listed appear unchanged by the refresh. The revision is notable mainly because it signals continued active maintenance of the alert during a period of heightened peptide-import enforcement.

DWPE is grounded in Section 801 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 381). Section 801(a) lets FDA refuse admission to an imported article that 'appears' to be adulterated, misbranded, or to be an unapproved new drug. The word 'appears' is the operative legal threshold: FDA does not need to prove a violation by testing the specific parcel. Per FDA's import-alert guidance, documented prior evidence about a firm, a product, or a class of products can be enough to make a new shipment 'appear' violative, which is what makes detention 'without physical examination' possible.

In practice this inverts the usual burden. For a product subject to DWPE, FDA's guidance indicates the shipment is detained and headed toward refusal unless the importer affirmatively overcomes the appearance of a violation by submitting evidence to the relevant FDA division compliance office that the product does not carry the listed violation. For unapproved new drugs, FDA notes this is difficult by definition: the cited deficiency is the absence of an approved application, which a single document submission cannot cure.

• FDA identifies a violation and adds a firm or product to an import alert's Red List.
• Future shipments matching the alert's criteria are flagged in FDA's screening system at entry.
• The shipment may be detained without being opened or tested ('without physical examination').
• The importer receives a Notice of FDA Action and may respond with evidence to overcome the apparent violation.
• Absent sufficient evidence, the article is refused admission and must be exported or destroyed.

According to FDA's industry FAQs, each import alert organizes entities into three lists, and which list a firm or product sits on determines its treatment at the border. Firms and products on the Red and Yellow lists are subject to scrutiny under the alert; only the Green list confers exemption. Moving from Red to Green is described by FDA as a formal process, not an automatic reclassification.

According to FDA, to be removed from a Red List a firm may submit a petition for removal from DWPE to FDA's import-alert mailbox (importalerts2@fda.hhs.gov). FDA weighs the totality of the evidence; the required elements vary by alert, product, and the nature of the problem. For an unapproved-new-drug charge, the practical path to removal generally requires resolving the regulatory status of the product itself, not merely documenting a single clean shipment.

Many research peptides circulating in the import stream have no FDA-approved drug application for the use being promoted, which can place them within the 'unapproved new drug' category that 66-41 and its sibling alerts target. FDA's stated rationale is that unapproved new drugs have not been reviewed for safety, effectiveness, manufacturing consistency, or labeling accuracy. According to legal and trade commentary, the agency typically pairs an unapproved-new-drug charge under Section 505 with misbranding charges under Section 502 of the FD&C Act.

A 'research use only' (RUO) label does not, by itself, create an importation exemption. FDA and customs authorities have signaled in 2025 and 2026, according to legal reporting, that they evaluate the actual marketed and intended use of a substance, not only the disclaimer printed on it. Where a vendor's advertising frames an RUO-labeled peptide for human use, that promotion can become the evidence used to treat the product as an unapproved new drug. In September 2025, FDA issued a wave of warning letters, reported as more than 50, to firms marketing compounded GLP-1 and other peptides, including semaglutide, tirzepatide, retatrutide, and BPC-157, in ways that, according to FDA, indicated human-use intent.

FDA's import alerts operate alongside U.S. Customs and Border Protection (CBP) enforcement at ports and mail facilities. CBP physically interdicts parcels; FDA's import alerts provide the regulatory basis to detain and refuse the merchandise. CBP and FDA reporting indicates the combination has driven a visible escalation in peptide interdictions across the mail, express-consignment, and air-cargo environments in 2025 and 2026.

A prominent recent example is a Cincinnati operation described in a CBP newsroom release. According to CBP, officers at the Port of Cincinnati identified more than 300 master-carton smuggling attempts from a shipper in China, with each carton concealing roughly 15 unmanifested, pre-labeled parcels, for a total of approximately 5,000 individual peptide shipments seized between December 2025 and 25 March 2026. CBP states the seized material included GLP-1 active ingredients such as retatrutide, semaglutide, and tirzepatide. Secondary reporting has also described other peptides as reportedly present in the operation; ChemVerify could not independently confirm those additional names against the primary CBP text. These figures should be read as the reported scale of a single operation, not aggregate national totals.

Import Alert 66-41 is not the only instrument FDA uses against peptide imports. According to FDA and legal commentary, it sits within a cluster of overlapping 66-series alerts. Researchers tracking a specific substance should check which alert and which list a product or supplier appears on, because the consequences differ by alert and by list placement.

Because list placement and alert membership are updated over time, the authoritative reference is always FDA's live import-alert page for the specific alert and the firm or product in question. ChemVerify reports these as regulatory facts; we do not provide guidance on importing, using, or administering any substance.

According to FDA's published change note, the 19 May 2026 revision updated the alert's guidance section, including its agency-contact information, rather than changing the DWPE legal mechanism or the list structure. The core authority — detaining unapproved new drugs without physical examination under Section 801 — is described as unchanged.

Section 801(a) of the FD&C Act lets FDA refuse an import that merely 'appears' to be in violation. Per FDA's guidance, documented prior evidence about a firm, product, or product class can be sufficient to create that appearance, so FDA's automated screening can flag and detain a matching shipment at entry without opening or testing it. The importer then carries the burden of submitting evidence to overcome the apparent violation.

No. According to legal reporting on FDA and CBP enforcement, an RUO label does not create an importation exemption. Authorities have indicated they assess the actual marketed and intended use of a substance, and promotional material framing a peptide for human use can itself support an unapproved-new-drug determination. The disclaimer does not, on its own, change a product's regulatory status at the border.

Per FDA's industry FAQs, Red List firms or products are subject to detention without physical examination under the alert; their shipments are detained and headed toward refusal unless the importer overcomes the apparent violation. Green List firms or products are excluded from the alert's criteria and are not subject to DWPE under that alert. Moving from Red to Green requires a formal petition and evidence reviewed by FDA.

Recent FDA warning letters and CBP seizures have named GLP-1 active ingredients including semaglutide, tirzepatide, and retatrutide, as well as other peptides such as BPC-157, according to FDA and CBP reporting. List placement changes over time, so the authoritative source for any specific substance is FDA's live import-alert record for the relevant alert and supplier.

Import Alert 66-41 targets unapproved new drugs promoted in the U.S. broadly, while 66-78 is described as focused on specific unapproved peptide drug substances and, per legal reporting, was expanded in 2025 to add further peptides. Both enable DWPE; the difference is scope and the specific products listed. A given peptide or supplier may appear under one alert, both, or neither, which is why checking the live FDA records for each is necessary.

• Are Research Peptides Legal? -> /learn/are-research-peptides-legal
• Research-Use-Only (RUO) Legal Status for Peptides: Complete Guide -> /learn/research-use-only-ruo-legal-status-for-peptides-complete-guide
• FDA Peptide Reclassification 2026: 14 Peptides Return to Category 1 -> /learn/fda-peptide-reclassification-2026-14-peptides-return-to-category-1
• Verify a Peptide COA -> /verify
• Compare Verified Peptide Sources -> /compare